Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Honghui Zhou

Showing results (31-40 of 143) with videos related to

Pageof 15
Sort By:
Journal of Clinical Pharmacology|October 20, 2009
Interspecies scaling of therapeutic monoclonal antibodies: initial lookJie Ling, Honghui Zhou, Qun Jiao, et al.
Journal of Pharmacokinetics and Pharmacodynamics|June 21, 2011
Bounded outcome score modeling: application to treating psoriasis with ustekinumabChuanpu Hu, Newman Yeilding, Hugh M Davis, et al.
Journal of Clinical Pharmacology|October 22, 2004
Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritisHonghui Zhou, Philip R Mayer, Joseph Wajdula, et al.
Journal of Clinical Pharmacology|June 25, 2020
Model-Aided Adults-to-Children Pharmacokinetic Extrapolation and Empirical Body Size-Based Dosing Exploration for Therapeutic Monoclonal Antibodies-Is Allometry a Reasonable Choice?Yan Xu, Brooke A Langevin, Honghui Zhou, et al.
The AAPS Journal|December 16, 2005
Evidence of effectiveness: how much can we extrapolate from existing studies?Howard Lee, Dong-Seok Yim, Honghui Zhou, et al.
Journal of Pharmacokinetics and Pharmacodynamics|July 21, 2014
Latent variable indirect response joint modeling of a continuous and a categorical clinical endpointChuanpu Hu, Philippe O Szapary, Alan M Mendelsohn, et al.
The AAPS Journal|April 19, 2018
Investigation of the Mechanism of Therapeutic Protein-Drug Interaction Between Methotrexate and Golimumab, an Anti-TNFα Monoclonal AntibodyWeirong Wang, Jocelyn Leu, Rebecca Watson, et al.
Basic & Clinical Pharmacology & Toxicology|February 17, 2015
Non-Clinical Pharmacokinetics, Prediction of Human Pharmacokinetics and First-in-Human Dose Selection for CNTO 5825, an Anti-Interleukin-13 Monoclonal AntibodyIvo P Nnane, Zhenhua Xu, Honghui Zhou, et al.
The AAPS Journal|March 11, 2016
Development of a Physiologically Based Pharmacokinetic Model to Predict Disease-Mediated Therapeutic Protein-Drug Interactions: Modulation of Multiple Cytochrome P450 Enzymes by Interleukin-6Xiling Jiang, Yanli Zhuang, Zhenhua Xu, et al.
Clinical and Translational Science|September 28, 2021
Utilization of physiologically-based pharmacokinetic model to assess disease-mediated therapeutic protein-disease-drug interaction in immune-mediated inflammatory diseasesLujing Wang, Yang Chen, Wangda Zhou, et al.
Pageof 15

Showing results (31-40 of 143) with videos related to

Sort By:
Pageof 15
Journal of Clinical Pharmacology|October 20, 2009
Interspecies scaling of therapeutic monoclonal antibodies: initial lookJie Ling, Honghui Zhou, Qun Jiao, et al.
Journal of Pharmacokinetics and Pharmacodynamics|June 21, 2011
Bounded outcome score modeling: application to treating psoriasis with ustekinumabChuanpu Hu, Newman Yeilding, Hugh M Davis, et al.
Journal of Clinical Pharmacology|October 22, 2004
Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritisHonghui Zhou, Philip R Mayer, Joseph Wajdula, et al.
Journal of Clinical Pharmacology|June 25, 2020
Model-Aided Adults-to-Children Pharmacokinetic Extrapolation and Empirical Body Size-Based Dosing Exploration for Therapeutic Monoclonal Antibodies-Is Allometry a Reasonable Choice?Yan Xu, Brooke A Langevin, Honghui Zhou, et al.
The AAPS Journal|December 16, 2005
Evidence of effectiveness: how much can we extrapolate from existing studies?Howard Lee, Dong-Seok Yim, Honghui Zhou, et al.
Journal of Pharmacokinetics and Pharmacodynamics|July 21, 2014
Latent variable indirect response joint modeling of a continuous and a categorical clinical endpointChuanpu Hu, Philippe O Szapary, Alan M Mendelsohn, et al.
The AAPS Journal|April 19, 2018
Investigation of the Mechanism of Therapeutic Protein-Drug Interaction Between Methotrexate and Golimumab, an Anti-TNFα Monoclonal AntibodyWeirong Wang, Jocelyn Leu, Rebecca Watson, et al.
Basic & Clinical Pharmacology & Toxicology|February 17, 2015
Non-Clinical Pharmacokinetics, Prediction of Human Pharmacokinetics and First-in-Human Dose Selection for CNTO 5825, an Anti-Interleukin-13 Monoclonal AntibodyIvo P Nnane, Zhenhua Xu, Honghui Zhou, et al.
The AAPS Journal|March 11, 2016
Development of a Physiologically Based Pharmacokinetic Model to Predict Disease-Mediated Therapeutic Protein-Drug Interactions: Modulation of Multiple Cytochrome P450 Enzymes by Interleukin-6Xiling Jiang, Yanli Zhuang, Zhenhua Xu, et al.
Clinical and Translational Science|September 28, 2021
Utilization of physiologically-based pharmacokinetic model to assess disease-mediated therapeutic protein-disease-drug interaction in immune-mediated inflammatory diseasesLujing Wang, Yang Chen, Wangda Zhou, et al.
Pageof 15